Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morand, E.F.
Right arrow Articles by Littlejohn, G.O.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Morand, E.F.
Right arrow Articles by Littlejohn, G.O.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 3, No. 3, 187-191 (1994)
DOI: 10.1177/096120339400300310

Fibromyalgia Syndrome and Disease Activity in Systemic Lupus Erythematosus

E.F. Morand

Monash Rheumatology Unit, Monash Medical Centre, Melbourne

M.H. Miller

Monash Rheumatology Unit, Monash Medical Centre, Melbourne

S. Whittingham

Bumet Clinical Research Unit, Walter and Eliza Hall Institute for Medical Research, Parkville, Australia

G.O. Littlejohn

Monash Rheumatology Unit, Monash Medical Centre, Melbourne

To study the effect of fibromyalgia syndrome (FS) on the expression of systemic lupus erythematosus (SLE) and on the measurement of disease activity, we performed a cross-sectional study of subjects with SLE. Eighty-seven subjects were studied and 22 (25.3%), all female, had FS (Yunus' criteria). Disease activity and organ system involvement were assessed using the systemic lupus activity measure (SLAM) and using 10 cm visual analogue scales (VAS) completed by both physician and patient. No significant difference between FS and non-FS groups in the objective measurement of disease activity was present, median (range) SLAM scores being 5 (0-18) and 6 (0-24), respectively (NS). Similarly, expression of SLE, as measured by the prevalence of specific organ system involvement, was similar in the two groups. In contrast the prevalence of glucocorticoid use, antibodies to DSDNA and fulfilling four ACR criteria was higher in the non-FS group. The rating of SLE disease activity was affected by concomitant FS. Physician and patient disease activity VAS correlated significantly with SLAM scores in non-FS subjects (P < 0.001, Spearman analysis), whereas in FS subjects, neither physician nor patient VAS correlated with SLAM scores. We conclude that FS is prevalent in individuals with SLE and does not affect disease expression but may interfere with the rating of disease activity.

Key Words: Systemic lupus erythematosus • Fibromyalgia syndrome • Disease activity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann Rheum DisHome page
G S Alarcon, J Calvo-Alen, G McGwin Jr, A G Uribe, S M A Toloza, J M Roseman, M Fernandez, B J Fessler, L M Vila, C Ahn, et al.
Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.
Ann Rheum Dis, September 1, 2006; 65(9): 1168 - 1174.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
M. Harth and J. Pope
The measure of our measures
Rheumatology, December 1, 2004; 43(12): 1465 - 1467.
[Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
S. Tang, H. Calkins, and M. Petri
Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia
Rheumatology, May 1, 2004; 43(5): 609 - 614.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M Valencia-Flores, M H Cardiel, V Santiago, M Resendiz, V A Castano, O Negrete, C Rosenberg, G Garcia-Ramos, J Alcocer, and D Alarcon-Segovia
Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus
Lupus, January 1, 2004; 13(1): 4 - 10.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
J. Taylor, J. Skan, N. Erb, D. Carruthers, S. Bowman, C. Gordon, and D. Isenberg
Lupus patients with fatigue--is there a link with fibromyalgia syndrome?
Rheumatology, June 1, 2000; 39(6): 620 - 623.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
J. C Yen, C. Neville, and P. R Fortin
Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials
Lupus, October 1, 1999; 8(8): 660 - 670.
[Abstract] [PDF]


Home page
LupusHome page
A Lopez-Osa, J Jimenez-Alonso, A Garcia-Sanchez, C Sanchez-Tapia, M Perez, M I Peralta, F Gutierrez-Cabello, and G Morente
Fibromyalgia in Spanish patients with systemic lupus erythematosus
Lupus, May 1, 1999; 8(4): 332 - 333.
[PDF]


Home page
LupusHome page
R. Bennett
Review : The concurrence of lupus and fibromyalgia: implications for diagnosis and management
Lupus, January 1, 1997; 6(6): 494 - 499.
[PDF]